Clinical Trial

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.
Protocol Amendment History 3 changes
notable Trial sites expanded: 1 -> 9 locations 2026-08-07
notable Primary completion pushed: 2026-10-31 -> 2027-12-31 2026-08-07
minor Completion pushed: 2026-10-31 -> 2027-12-31 2026-08-07
Trial Details
NCT Number NCT06610266
Lead Sponsor Yongquan Shi
Conditions Gastric Intestinal Metaplasia
Enrollment 400 participants
Start Date 2025-02-28
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06